Company intelligence / Profile preview
3T Biosciences
South San Francisco, California, United States3tbiosciences.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
3T Biosciences is developing next-generation immunotherapies for solid tumors and immune-mediated diseases. The company has exclusively licensed a peptide-HLA therapeutic discovery platform and development-stage MAGE-A3 TCR-T assets from Stanford University.
- Therapeutic areas
- OncologyImmunology
- Modalities
- T-cell receptor (TCR) therapeuticsTCR-mimetics (TCRm)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Stanford UniversityBoehringer Ingelheim
Beyond the preview
Go deeper on 3T Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 3T Biosciences.